Formycon AG (FRA:FYB)
23.10
-0.25 (-1.07%)
At close: Oct 23, 2025
Formycon AG Employees
Formycon AG had 250 employees as of December 31, 2024. The number of employees increased by 12 or 5.04% compared to the previous year.
Employees
250
Change (1Y)
12
Growth (1Y)
5.04%
Revenue / Employee
€211,339
Profits / Employee
€692,939
Market Cap
408.05M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 250 | 12 | 5.04% |
| Dec 31, 2023 | 238 | 33 | 16.10% |
| Dec 31, 2022 | 205 | 34 | 19.88% |
| Dec 31, 2021 | 171 | 40 | 30.53% |
| Dec 31, 2020 | 131 | 18 | 15.93% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Siemens Aktiengesellschaft | 327,000 |
| Deutsche Telekom AG | 198,194 |
| Mercedes-Benz Group AG | 175,264 |
| Allianz SE | 156,626 |
| SAP SE | 109,121 |
| Siemens Energy AG | 98,000 |
| Deutsche Bank Aktiengesellschaft | 89,753 |
| Siemens Healthineers AG | 72,000 |
Formycon AG News
- 3 days ago - Formycon, Teva Pharma Launch FYB201/Ranivisio Biosimilar In Pre-filled Syringe In Europe - Nasdaq
- 3 days ago - EQS-News: Formycon’s FYB201/Ranivisio sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe - Wallstreet:Online
- 8 days ago - EQS-News: Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea biosimilar FYB203 (aflibercept) for Australia and Latin America - Wallstreet:Online
- 16 days ago - EQS-AFR: Formycon AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements - Wallstreet:Online
- 22 days ago - Formycon Reaches Settlement With Regeneron Over U.S. Eylea Biosimilar Patent Disputes - Nasdaq
- 22 days ago - EQS-News: Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron - Wallstreet:Online
- 24 days ago - EQS-NVR: Formycon AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution - Wallstreet:Online
- 5 weeks ago - Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy • news - Onvista